Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  entinostat
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-17 of 17 for your search:
Start Over
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00220, CDR0000504083, NA_00003114, J0658, 7759, P30CA006973, U01CA070095, JHOC-J0658, NCT00387465
Study to Evaluate Erlotinib With or Without SNDX-275 in the Treatment of Patients With Advanced NSCLC
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SNDX-275-0401, NCT00602030
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-01077, E1905, U10CA021115, ECOG-E1905, NCT00313586
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00195, J06114, U01CA070095, JHOC-J06114, 7605, NA_00006989, NCT00462605
Study to Evaluate Exemestane With and Without SNDX-275 in Treatment of Postmenopausal Women With Advanced Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SNDX-275-0301, NCT00676663
A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Patients With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: SNDX-275-0403, NCT00750698
A Phase 2, Multicenter Study of the Effect of the Addition of SNDX-275 to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
Phase: Phase II
Type: Treatment
Status: Completed
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: SNDX-275-0303, NCT00828854
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SNDX-275-0501, NCT00866333
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2010-02024, CDR0000670136, MC084B, 8341, N01CM00099, P30CA015083, N01CM00038, MAYO-MC084B, NCT01105377
A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 60 and over
Sponsor: Other
Protocol IDs: J1093, NCT01305499
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02585, CDR0000698726, SKCCC J1107, 8822, N01CM00038, N01CM62205, P30CA006973, U01CA062505, U01CA070095, MAYO-MC1035, MC1035, NCT01349959
MS-275 in Treating Patients With Hematologic Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068574, J0253, U01CA069854, P30CA006973, JHOC-J0253, MSGCC-0050, NCI-2791, NCT00015925
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02634, JHOC-J0438, U01CA070095, CDR0000396776, 6798, NCI-6798, JHOC-04060103, NCT00098891
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00071, CDR0000405841, J0443, 6591, P30CA006973, U01CA070095, JHOC-J0443, NCI-6591, JHOC-04061109, NCT00101179
Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 21 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01436, CDR0000671796, JHOC-MD017, J09112, 8298, U01CA070095, P30CA006973, SKCCC-MD017, NCT01132573
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 to 90
Sponsor: Pharmaceutical / Industry
Protocol IDs: SNDX-275-0110, NCT01594398
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, NIH WGMCC
Protocol IDs: 010124, 01-C-0124, NCI-2792, CDR0000068615, NCI-01-C-0124, 2792, NCT00020579
Start Over